vs
CUMBERLAND PHARMACEUTICALS INC（CPIX）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
CUMBERLAND PHARMACEUTICALS INC的季度营收约是Lakeside Holding Ltd的2.0倍（$13.7M vs $7.0M），CUMBERLAND PHARMACEUTICALS INC净利率更高（-10.3% vs -22.6%，领先12.3%），Lakeside Holding Ltd同比增速更快（95.0% vs 31.1%）
坎伯兰制药是一家专科制药企业，专注于开发、生产和商业化品牌处方药物，核心产品覆盖急症护理、胃肠病、疼痛管理及罕见病治疗领域，主要运营市场为美国，为相关医护人员与患者提供服务。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
CPIX vs LSH — 直观对比
营收规模更大
CPIX
是对方的2.0倍
$7.0M
营收增速更快
LSH
高出64.0%
31.1%
净利率更高
CPIX
高出12.3%
-22.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.7M | $7.0M |
| 净利润 | $-1.4M | $-1.6M |
| 毛利率 | 83.6% | 27.2% |
| 营业利润率 | -10.0% | -21.3% |
| 净利率 | -10.3% | -22.6% |
| 营收同比 | 31.1% | 95.0% |
| 净利润同比 | 25.8% | 18.7% |
| 每股收益（稀释后） | $-0.09 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPIXLSH
| Q4 25 | $13.7M | $7.0M | ||
| Q3 25 | $8.3M | $6.1M | ||
| Q2 25 | $10.8M | $6.3M | ||
| Q1 25 | $11.7M | $3.8M | ||
| Q4 24 | $10.4M | $3.6M | ||
| Q3 24 | $9.1M | $4.1M | ||
| Q2 24 | $9.8M | — | ||
| Q1 24 | $8.5M | — |
净利润CPIXLSH
| Q4 25 | $-1.4M | $-1.6M | ||
| Q3 25 | $-1.9M | $-1.4M | ||
| Q2 25 | $-740.7K | $-893.1K | ||
| Q1 25 | $1.3M | $-1.1M | ||
| Q4 24 | $-1.9M | $-1.9M | ||
| Q3 24 | $-1.5M | $-1.3M | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | $-1.9M | — |
毛利率CPIXLSH
| Q4 25 | 83.6% | 27.2% | ||
| Q3 25 | 88.1% | 18.2% | ||
| Q2 25 | 81.4% | 26.7% | ||
| Q1 25 | 87.8% | 18.8% | ||
| Q4 24 | 81.1% | -1.2% | ||
| Q3 24 | 85.4% | 12.8% | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 81.5% | — |
营业利润率CPIXLSH
| Q4 25 | -10.0% | -21.3% | ||
| Q3 25 | -23.7% | -20.8% | ||
| Q2 25 | -6.9% | -8.9% | ||
| Q1 25 | 11.0% | -28.2% | ||
| Q4 24 | -17.7% | -55.6% | ||
| Q3 24 | -18.6% | -32.5% | ||
| Q2 24 | -10.4% | — | ||
| Q1 24 | -22.0% | — |
净利率CPIXLSH
| Q4 25 | -10.3% | -22.6% | ||
| Q3 25 | -23.4% | -22.2% | ||
| Q2 25 | -6.8% | -14.2% | ||
| Q1 25 | 10.7% | -28.2% | ||
| Q4 24 | -18.2% | -54.1% | ||
| Q3 24 | -17.0% | -32.7% | ||
| Q2 24 | -11.0% | — | ||
| Q1 24 | -22.9% | — |
每股收益（稀释后）CPIXLSH
| Q4 25 | $-0.09 | $-0.08 | ||
| Q3 25 | $-0.13 | $-0.09 | ||
| Q2 25 | $-0.05 | $-0.11 | ||
| Q1 25 | $0.08 | $-0.14 | ||
| Q4 24 | $-0.13 | $-0.26 | ||
| Q3 24 | $-0.11 | $-0.18 | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $24.9M | $12.2M |
| 总资产 | $76.8M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资CPIXLSH
| Q4 25 | $11.4M | $1.6M | ||
| Q3 25 | $15.2M | $4.5M | ||
| Q2 25 | $16.1M | $5.0M | ||
| Q1 25 | $15.1M | $1.5M | ||
| Q4 24 | $18.0M | $1.1M | ||
| Q3 24 | $17.5M | $2.7M | ||
| Q2 24 | $17.3M | — | ||
| Q1 24 | $18.5M | — |
总债务CPIXLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CPIXLSH
| Q4 25 | $24.9M | $12.2M | ||
| Q3 25 | $26.1M | $7.0M | ||
| Q2 25 | $28.0M | $2.8M | ||
| Q1 25 | $28.7M | $749.8K | ||
| Q4 24 | $22.9M | $1.6M | ||
| Q3 24 | $24.8M | $3.6M | ||
| Q2 24 | $26.3M | — | ||
| Q1 24 | $27.5M | — |
总资产CPIXLSH
| Q4 25 | $76.8M | $24.3M | ||
| Q3 25 | $65.9M | $18.6M | ||
| Q2 25 | $67.9M | $14.4M | ||
| Q1 25 | $69.9M | $9.9M | ||
| Q4 24 | $75.6M | $9.8M | ||
| Q3 24 | $76.7M | $10.8M | ||
| Q2 24 | $78.5M | — | ||
| Q1 24 | $81.5M | — |
负债/权益比CPIXLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0K | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $3.0K | — |
| 自由现金流率自由现金流/营收 | 0.0% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $4.8M | — |
8季度趋势，按日历期对齐
经营现金流CPIXLSH
| Q4 25 | $3.0K | $-453.5K | ||
| Q3 25 | $187.2K | $-4.0M | ||
| Q2 25 | $843.8K | $-483.7K | ||
| Q1 25 | $3.9M | $-238.3K | ||
| Q4 24 | $1.9M | $-530.2K | ||
| Q3 24 | $475.5K | $-1.4M | ||
| Q2 24 | $-855.7K | — | ||
| Q1 24 | $-2.1M | — |
自由现金流CPIXLSH
| Q4 25 | $3.0K | — | ||
| Q3 25 | $163.4K | — | ||
| Q2 25 | $817.3K | $-497.4K | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $1.9M | $-560.5K | ||
| Q3 24 | $460.1K | $-1.4M | ||
| Q2 24 | $-862.8K | — | ||
| Q1 24 | $-2.2M | — |
自由现金流率CPIXLSH
| Q4 25 | 0.0% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 7.5% | -7.9% | ||
| Q1 25 | 32.9% | — | ||
| Q4 24 | 18.2% | -15.6% | ||
| Q3 24 | 5.1% | -34.5% | ||
| Q2 24 | -8.8% | — | ||
| Q1 24 | -25.6% | — |
资本支出强度CPIXLSH
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.2% | 0.2% | ||
| Q1 25 | 0.4% | 0.0% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
现金转化率CPIXLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPIX
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
